Results 61 to 70 of about 2,368 (193)

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

open access: yesThe Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta   +2 more
wiley   +1 more source

Impact du nirsevimab sur les infections pédiatriques au VRS en Belgique en 2024-2025 : une analyse des données de surveillance sentinelle de routine de Sciensano

open access: yes
Nous estimons que 35 à 45 % des hospitalisations ont été évitées grâce à l’introduction du nirsevimab. Nous estimons que l’introduction du nirsevimab a permis de diminuer de 35 à 45 % les hospitalisations liées à une infection au VRS chez les enfants de ...
T. Braeye   +15 more
core   +1 more source

Impact van nirsevimab op pediatrische RSV-infecties in België in 2024-2025. Een analyse van de routine sentinel-surveillancegegevens van Sciensano

open access: yes
We schatten dat 35 tot 45% van de ziekenhuisopnames is voorkomen door de introductie van nirsevimab. We schatten dat de introductie van nirsevimab heeft geleid tot 35-45% minder ziekenhuisopnames voor een RSV-infectie bij kinderen jonger dan 5 jaar.
T. Braeye   +15 more
core   +1 more source

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France

open access: yesThe Lancet Microbe
Summary: Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants. Nirsevimab, a long-acting monoclonal antibody targeting a conserved epitope on the prefusion F protein (site Φ), has shown high ...
ProfPhD Slim Fourati   +202 more
doaj   +1 more source

Palivizumab for Donor‐Derived RSV Infection in an Adult Bilateral Lung Transplant Recipient: A Case Report

open access: yesRespirology Case Reports, Volume 14, Issue 8, August 2026.
We describe the use of off‐label palivizumab in an early post‐operative bilateral lung transplant recipient with probable donor‐derived RSV who developed persistent severe LRTI and respiratory failure. RSV PCR Ct fell and remained low from day 0 to day 42 despite conventional therapy until palivizumab was administered on day 44, following which we ...
Rosemary Meharry   +2 more
wiley   +1 more source

Results From the Third and Fourth WHO External Quality Assessments for the Molecular Detection of Respiratory Syncytial Virus

open access: yesInfluenza and Other Respiratory Viruses, Volume 20, Issue 8, August 2026.
ABSTRACT Background In 2016, the World Health Organization (WHO) initiated the global RSV surveillance programme, which aimed to strengthen laboratory diagnostic capacity and evaluate molecular detection test performance. External quality assessments (EQAs) are conducted regularly as part of this programme to ensure ongoing laboratory proficiency.
Fernando do Couto Motta   +11 more
wiley   +1 more source

Evaluating Analytic Approaches to Determining Respiratory Syncytial Virus Seasonality—United States, 2014–2024

open access: yesInfluenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background Respiratory syncytial virus (RSV) is a major cause of hospitalizations among infants and older adults in the United States. Determining RSV seasonality, which varies geographically, is essential to the timely administration of prevention products.
Sophia Chkonia   +5 more
wiley   +1 more source

Correlations and Timeliness of Respiratory Syncytial Virus Surveillance Indicators—United States, 2018–2024

open access: yesInfluenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background Respiratory syncytial virus (RSV) is a major cause of hospitalizations in young children and older adults in the United States. Monitoring seasonal RSV activity through national surveillance systems and understanding the relationships among RSV surveillance indicators can help ensure timely administration of prevention products and ...
Erin L. Anderson   +12 more
wiley   +1 more source

Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in Oceania

open access: yesJournal of Paediatrics and Child Health, Volume 62, Issue 7, Page 1113-1120, July 2026.
ABSTRACT Autosomal recessive interferon alpha and beta receptor subunit 1 (IFNAR1) deficiency is a rare and heritable inborn error of immunity (IEI) predisposing individuals to severe and life‐threatening viral infections. It is more common in people of Western Polynesian ancestry, with estimates of around one in six thousand live births affected, due ...
Cecilia Verryt   +17 more
wiley   +1 more source

Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season

open access: yes
The study was funded by the Institute of Health Carlos III (on its own budget) which, at the institutional level, had no role in the study design, data collection, analysis or interpretation.Using real-life data from Spain between October 2023 and March ...
Nuñez, Olivier   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy